This is a Phase 1/2 study designed to evaluate the safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma whose disease has progressed after 3 or more prior systemic therapies.
SparkCures ID | 929 |
---|---|
Trial Phase | Phase 1/2 |
Enrollment | 41 Patients |
Treatments | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Key Inclusion Criteria:
Individuals eligible to participate in this study must meet the following key criteria and additional criteria as specified in the protocol:
Key Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers